Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a female patient with both psoriasis and lichen planus initially responded to acitretin and topical mometasone but experienced a relapse after stopping the treatment. The authors reported marked improvement within 3 months after switching to upadacitinib, aiming to guide clinical decision-making.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

Infliximab was effective in treating a scalp condition that did not respond to other treatments.

A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.

This document provides a legal disclaimer and offers no research findings.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.

This study observed that patients receiving IL-2 immunotherapy developed a skin eruption characterized by burning and pruritus, which resolved shortly after stopping the infusion, suggesting that IL-2 mediated these effects.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

This study found that coadministration of pimecrolimus may interfere with the therapeutic efficacy of mesenchymal stem cell therapy in atopic dermatitis.

This review discusses the potential of combined therapy with WP 631 and epothilone B for ovarian cancer, but reports no new clinical results.

This study reported that dupilumab, a human monoclonal antibody, induced hair regrowth in patients with alopecia totalis, suggesting its potential as a treatment for this condition.

This case report suggests potential effectiveness of dupilumab for alopecia areata, though hair regrowth may result from indirect effects on inflammation in atopic dermatitis.

In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.

Adalimumab improved folliculitis decalvans in most patients.

This review synthesizes cases of biopsy-confirmed alopecia areata occurring in patients using IL-17 or IL-23 inhibitors, suggesting the need for increased awareness and further investigation into this rare adverse event.

This case study reports a rare instance of pembrolizumab-induced eyelash trichomegaly in a 63-year-old male patient, highlighting the importance for clinicians to be aware of such uncommon adverse effects to manage patient treatment effectively.

Brodalumab effectively treated a man's severe hand and foot psoriasis.

This study suggests that blood microarray biomarkers may help predict individual treatment response in psoriasis patients, highlighting a distinct blood signature related to inflammation, interferon, and myeloid lineage transcripts.

This study describes a case where stopping infliximab and using oral minocycline with topical treatments effectively resolved alopecia and scalp psoriasis in a woman with Crohn's disease.

This study found that patients with unresectable melanoma treated with AZD6244 experienced skin reactions, including depigmentation and papulopustular rashes, in patterns similar to those caused by EGFR inhibitors.

This study observed that 6.45% of IBD patients treated with anti-TNF therapy developed severe psoriasiform reactions, with notable cases of alopecia universalis suggesting a potential link to previous alopecia areata.

In this case report, a woman with ulcerative colitis experienced clinical deterioration during upadacitinib therapy, which improved after discontinuation, strongly suggesting drug hypersensitivity to the Janus kinase inhibitor as a potential cause for her symptoms.

This article reviews the differences in inflammatory processes between alopecia universalis and atopic dermatitis, focusing on type 1 and type 2 immune responses, but it reports no new results.

This study found that 3D imaging may serve as a promising tool for objectively evaluating facial vitiligo repigmentation after treatment with upadacitinib.

This review suggests that IL-23 inhibitors may be effective for various non-psoriatic inflammatory skin conditions, but emphasizes the need for further large-scale trials to confirm their efficacy and safety.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

In this study, 93% of patients with inflammatory arthritis remained on the adalimumab biosimilar ABP 501 for 24 weeks after switching from the originator, with some switching back due to adverse reactions or reduced effectiveness.